glp-1 cirrhosis Multiple target tissue effects of analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Glp–1 and cirrhosis: effects on

Discovery The development of GLP-1 based drugs for obesity did not happen overnight

Used to facilitate energy and weight loss

27 (5), e13211

Investors will hear initial sales figures when Novo reports first quarter earnings on May 6

Keywords: GLP-1 receptor agonists, Neuroprotection, Synaptic plasticity, Central nervous system, Neurodegenerative diseases Graphical abstract Introduction GLP-1 receptor agonists (GLP-1RAs) are well-established treatments for type 2 diabetes mellitus (T2DM) and obesity, providing effective glycemic control, weight loss, and cardiovascular benefits [[1], [2], [3]]

This alarming scenario of increasing obesity and overweight prevalence has directed human efforts to find out easily applicable dietary and lifestyle salvation tools